WPC Slider 1 Internal 2016B  
Archived Content

Targeting Alzheimer’s Disease


Day 1 | Day 2 
Download World Pharma Congress Final Brochure or Download Alzheimer Disease Brochure 

About This Conference:

The Targeting Alzheimer's Disease conference provides an opportunity to learn new methods, network with experts in Alzheimer’s disease research and have access to the latest technology in translational research, imaging, biomarker development, and target validation.


7:15 am Registration & Morning Coffee

Program Scientific Advisor: Corinne Augelli-Szafran, Ph.D., Director, Laboratory for Experimental Alzheimer Drugs (LEAD), Harvard Medical School, Department of Neurology Center for Neurologic Diseases Brigham and Women’s Hospital



8:30 Chairperson’s Opening Remarks

Marcelle Bergeron, Ph.D., Director, Neuropharmacology, Elan Pharmaceuticals

8:40 Preclinical Evaluation of Non-Motor Function as a Potential Source of Translatable Biomarkers for Parkinson’s Disease

Marcelle Bergeron, Ph.D., Director, Neuropharmacology, Elan Pharmaceuticals

The identification of translatable biomarkers for the diagnosis of the early stages of Parkinson’s disease (PD) could facilitate better targeted treatment strategies. Although preclinical models have been used to understand the etiological factors implicated in PD, much remain to be done to characterize reliable markers of disease onset that can also be used to track the efficacy of therapeutic agents.  Increasing evidence suggests that non-motor symptoms may occur before the characteristic motor dysfunction associated with PD.  This presentation will summarize some of this evidence and present examples in a novel preclinical PD model. 

9:10 Hunting for IgG Biomarkers for Alzheimer's

Dwight German, Ph.D., Professor, Department of Psychiatry, University of Texas Southwestern Medical Center

Using a 15,000 peptoid library, we have identified 3 Alzheimer’s disease (AD)-related peptoids that capture markedly elevated serum IgGs compared to those found in normal controls and those with Parkinson’s disease. These peptoids also appear to be useful for the identification of the early stage of AD, i.e., mild cognitive impairment. Future studies will further validate these biomarkers, and identify the antigens that are recognized by the IgG antibodies

9:40 Surgery and Anesthesia as Modifiers of Alzheimer’s Trajectory

Roderic G. Eckenhoff, M.D., Vice Chair for Research, Austin Lamont Professor of Anesthesiology & Critical Care, Perelman School of Medicine, University of Pennsylvania

Modern healthcare involves operative procedures that produce considerable stress, pain and inflammation.  These procedures occur more frequent in the elderly, and are often followed by cognitive decline which is occasionally irreversible and associated with excess morbidity and mortality. Recent work has suggested that the trajectory of incipient Alzheimer pathology may be accelerated by features of the perioperative period, such as anesthetics or inflammation. I will summarize evidence from both pre-clinical and clinical studies, and point to the essential role for reliable biomarkers.

10:10 Coffee Break

10:40 Selected Poster Presentation: An Amyloid Seeding Assay (ASA) for the Early Detection of Protein Misfolding

Sharad Gupta, Ph.D., Post-doctoral Fellow, Biochemical and Chemical Engineering, University of Delaware

Novel Approaches To Drug Discovery Through Alternative Targets

11:10 Novel NMDA Receptor Antagonists for Treatment of AD

Adeboye Adejare, Ph.D., Professor, Pharmaceutical Sciences, University of the Sciences, Philadelphia College of Pharmacy

Apart from cholinesterase inhibitors, the only FDA approved drug for treatment of AD (memantine, Namenda®) is an NMDA receptor antagonist. In addition to decreasing over-excitation, several of the compounds are known to have anti-inflammatory and anti-oxidant properties. A recent development is that these compounds can modulate APP metabolism. The talk will focus on development of superior NMDA receptor antagonists acting by several mechanisms and the possibility of their use for AD treatment.

11:40 PP2A – A Novel Target for Alzheimer’s Disease Therapeutics

Steven Braithwaite, Ph.D., Senior Vice President, Drug Discovery, Neuroscience, Signum Biosciences

Phosphoprotein phosphatase 2A (PP2A) is the master regulator of tau phosphorylation state and a central regulator of cellular function. Our identification of a safe and efficacious mechanism to enhance PP2A activity indicates that it is a drugable target. We have identified compounds targeting this mechanism that display efficacy in multiple models of Alzheimer's disease - modulating critical biochemical and pathological processes and improving cognition. PP2A therefore stands as a novel and tractable disease modifying target for Alzheimer's disease.

12:10 pm Luncheon Presentation

Development of Analytically Validated CSF Biomarker Assays for Alzheimer’s Disease

Pankaj Oberoi, Ph.D., Director, Scientific Services and Research & Development, Meso Scale Discovery


1:10 Session Break


Corinne Augelli-Szafran, Ph.D., Director, Laboratory for Experimental Alzheimer Drugs (LEAD), Harvard Medical School, Department of Neurology Center for Neurologic Diseases Brigham and Women’s Hospital

1:25 Enhancing Antibody Uptake in Brain to Target BACE1

Jasvinder K. Atwal, Ph.D., Senior Research Associate, Neuroscience, Genentech


Maccine1:55 Translation in Alzheimer’s Disease: Value Added through Preclinical in vivo Testing in the Primate?

Jeffrey A. Vivian, Ph.D., Department of Neuroscience, Maccine Pte Ltd

The development of Alzheimer’s drugs has been hampered by poor preclinical methods predicting clinical efficacy, and often a corresponding lack of biomarkers to confirm target engagement. Nonhuman primates offer advantages in the assessment of novel pharmacotherapies as the methods employed (CANTAB) and biochemical endpoints (CSF A-beta) are the same as those deployed in the clinic. In this presentation, we will provide data which marshal support for the utility of nonhuman primates for cognitive endpoints with a focus on treatments for Alzheimer’s Disease.

2:10 Moderated Speaker Q&A Panel

Moderator: Corinne Augelli-Szafran, Ph.D., Director, Laboratory for Experimental Alzheimer Drugs (LEAD), Harvard Medical School, Department of Neurology; Center for Neurologic Diseases Brigham and Women’s Hospital

Speakers from the neurodegenerative biomarker and novel target session will address current topics in AD research.
Audience participation is encouraged and the moderator will have prepared questions for the panelists.


Converting Knowledge of Ab Biology into Disease-Modifying Therapeutics

Dennis SelkoeDennis J. Selkoe, M.D., Vincent and Stella Coates Professor of Neurologic Diseases, Harvard Medical School; Co-Director, Center for Neurologic Diseases, Brigham and Women’s Hospital

The central quest of research on Alzheimer’s disease is to identify precisely what process first interferes with episodic declarative memory and then prevent that process. Soluble Aß oligomers isolated directly from AD cortex impair synaptic form and function and induce tau hyperphosphorylation and neuritic dystrophy. Based on this knowledge, attempts to develop effective A-lowering agents have brought us to human trials that have provided preliminary evidence of apparent cognitive and biomarker benefit.



Alzheimer’s Targets and the Path to the Clinic with Dennis Selkoe and Corinne Augelli-Szafran
Download the podcast! 

3:40 Refreshment Break in the Exhibit Hall with Poster Viewing

4:40 Interactive Discussion Groups 

Animal Models for AD and PD- Should we Skip the Preclinical Models?

  • AD models have failed to meet disease state
  • Cognition and other symptoms—can we mimic them in animals?
  • Will transgenic and induced models ever be true predictors for neurodegenerative drug discovery?

Moderator: Susan E. Browne, Ph.D., Director, Neuropharmacology, Merck Research Labs

Drug Discovery in Animal Models of Neurodegenerative Diseases 

  • Discuss methods that would ameliorate translation between basic and clinical research.
  • How can we improve development and testing of animal models: rigor? Standardization? New measures (bring in cubes/informatics)
  • Publication bias and its impact on research and cost of discovery

Moderator: Sylvie Ramboz, Ph.D., Vice President, Neurodegenerative Disorders, PsychoGenics


5:40 Welcome Reception in the Exhibit Hall with Poster Viewing

6:45 End of Day

Day 1 | Day 2 
Download World Pharma Congress Final Brochure or Download Alzheimer Disease Brochure 

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  



WPC Quotes